Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: Preclinical studies

Blood

Volumn 94, Issue 10, 1999, Pages 3531-3540

  Cardoso, Angelo A ^a   Veiga, J Pedro ^b   Ghia, Paolo ^b   Afonso, Hernani M ^b   Haining, W Nicholas ^b   Sallan, Stephen E ^b   Nadler, Lee M ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ARTICLE; B CELL LEUKEMIA; BONE MARROW; CELL ADHESION; CELL MEDIATED CYTOTOXICITY; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE; VASCULAR ENDOTHELIUM;

EID: 0033571661     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.10.3531.422k14_3531_3540     Document Type: Article

References (59)

1. Lotzova E, Savary CA, Keating MJ: Studies on the mechanism of defective natural killing in leukemia-diseased patients. Exp Hematol 10:83, 1982
2. Lotzova E, Savary CA, Herberman RB: Impaired NK cell profile in leukemia patients, in Lotzova E, Herberman RB (eds): Immunobiology of Natural Killer Cells, vol 2. Basel, Switzerland, Karger, 1986, p 29
3. Adler A, Chervenick PA, Whiteside TL, Lotzova E, Herberman RB: Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71:709, 1988
4. Foa R, Fierro MT, Cesano A, Guarini A, Bonferroni M, Raspadori D, Miniero R, Lauria F, Gavosto F: Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease. Blood 78:1041, 1991
5. Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H: Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 68:938, 1986
6. Findley HW, Mageed AA, Nasr SA, Ragab AH: Recombinant interleukin-2 activates peripheral blood lymphocytes from children with acute leukemia to kill autologous leukemic cells. Cancer 62:1928, 1988
7. Adler A, Albo V, Blatt J, Whiteside TL, Herberman RB: Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission. Blood 74:1690, 1989
8. Fisch P, Weil-Hillman G, Uppenkamp M, Hank JA, Chen BP, Sosman JA, Bridges A, Colamonici OR, Sondel PM: Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemia. Blood 74:343, 1989
9. Archimbaud E, Thomas E, Campos L, Magaud J-P, Fiere D, Dore J-F: Susceptibility of adult acute lymphoblastic leukemia blasts to lysis by lymphokine-activated killer cells. Leukemia 5:967, 1991
10. Parrado A, Rodriguez-Fernandez J-M, Casares S, Noguerol P, Plaza E, Parody R, Espigado I, Blas J-M, Garcia-Solis D: Generation of LAK cells in vitro in patients with acute leukemia. Leukemia 7:1344, 1993
11. Bensussan A, Lagabrielle J-F, Degos L: TCRγδ beraing lymphocyte clones with lymphokine-activated killer activity against autologous leukemic cells. Blood 73:2077, 1989
12. Duval M, Yotnda P, Bensussan A, Oudhiri N, Guidal C, Rohrlich P, Boumsell L, Grandchamp B, Vilmer E: Potential antileukemic effect of 78 T cells in acute lymphoblastic leukemia. Leukemia 9:863, 1995
13. Cardoso AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S, Billet A, Sallan SE, Gribben JG, Nadler LM: Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 88:41, 1996
14. Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, Gribben JG, Sallan SE, Nadler LM: Ex-vivo generation of anti-pre-B leukemia specific autologous cytolytic T cells. Blood 90:549, 1997
15. Almeida-Porada G, Ascensao JL: Isolation, characterization, and biologic features of bone marrow endothelial cells. J Lab Clin Med 128:399, 1996
16. Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Lansdorp PM: Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 74:1563, 1989
17. Eaves CJ, Cashman JD, Eaves AC: Methodology of long-term culture of human hemopoietic cells. J Tiss Cult Methods 13:55, 1991
18. Lane P, Brocker T, Hubele S, Padovan E, Lanzavechia A, McConnell F: Soluble CD40-ligand can replace the normal T cell derived CD40-ligand signal to B cells in T-dependent activation. J Exp Med 177:1209, 1993
19. Huber AR, Kunkel SL, Todd RF III, Weiss SJ: Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science 254:99, 1991
20. Roth SJ, Carr MW, Rose SS, Springer TA: Caracterization of transendothelial chemotaxis of T lymphocytes. J Immunol Methods 188:97, 1995
21. Brunner KT, Mauel J, Cerottini JC, Chapuis B: Quantitative assay of the lytic action of immune lymphoid cells on 51Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14:181, 1968
22. Kroesen BJ: Direct visualisation and quantification of cellular cytotoxicity using two colour fluorescence. J Immunol Methods 156:47, 1992
23. Chang L: Rapid flow cytometric assay for the assessment of natural killer cell activity. J Immunol Methods 166:45, 1993
24. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, Lobb RR: VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60:577, 1990
25. Bazzoni G, Carlesso N, Griffin JD, Hemler ME: Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest 98:521, 1996
26. Chan BMC, Elices MJ, Murphy E, Hemler ME: Adhesion to VCAM-1 and fibronectin: Comparison of α4β1 (VLA-4) and α4β7 on the human cell line JY. J Biol Chem 267:8366, 1992
27. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital acute lymphoblastic leukemia consortium protocol 85-01. J Clin Oncol 12:740, 1994
28. Pui CH: Childhood leukemias. N Engl J Med 332:1618, 1995
29. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui C-H, Pullen J, Reaman G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R: Uniform approach to risk classification and treatment assignement for children with acute lymphoblastic leukemia. J Clin Oncol 14:18, 1996
30. Dilloo D, Brown M, Roskrow M, Zhong W, Holladay M, Holden W, Brenner M: CD40 ligand induces an antileukemia immune response in vivo. Blood 90:1927, 1997
31. Yotnda P, Garcia F, Peuchmaur M, Grandchamp B, Duval M, Lemonnier F, Vilmer E, Langlade-Demoyen P: Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest 102:455, 1998
32. Mackay CR: Migration pathways and immunologic memory among T lymphocytes. Semin Immunol 4:51, 1992
33. Mackay CR, Marston WL, Dudler L, Spertini O, Tedder TF, Hein WR: Tissue-specific migration pathway by phenotypically distinct subpopulations of memory T cells. Eur J Immunol 22:887, 1992
34. Mackay CR, Marston WL, Dudler L: Altered patterns of T cell migration through lymph nodes and skin following antigen challenge. Eur J Immunol 22:2205, 1992
35. Duquesnov RJ, Zeevi A, Fung JJ, Kaufman C, Zerbe TR, Griffith B, Trento A, Kormos R, Hardesty R: Sequential infiltration of class I and class II specific alloreactive T cells in human cardiac allografts. Transplant Proc 19:2560, 1987
36. Yamamoto H, Kinoshita H, Kinoshita Y, Mizoguchi S, Inuoe K, Kishi A: Immunohistochemical aspects of acute rejection of the allografted rat lung. Transplantation 49:631, 1990
37. Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R, Walker BD: Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 149:3339, 1992
38. Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: The multi-step paradigm. Cell 76:301, 1994
39. Girard J-P, Springer TA: High endothelial venules (HEVs): Specialized endothelium for lymphocyte migration. Immunol Today 16:449, 1995
40. + blood T cells through endothelial cell monolayers in vitro. J Leukoc Biol 58:317, 1995
41. Kitayama J, Juji T, Atomi Y, Kuroda A, Muto T, Kobayashi M, Mitsui Y, Minami M: Transendothelial migration of lymphokine-activated killer (LAK) cells. J Immunol 151:1663, 1993
42. Damle NK, Doyle LV, Bender JR, Bradley EC: Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol 138:1779, 1987
43. Kotasek DK, Vercellotti GM, Ochoa AC, Bach FH, White JG, Jacob HS: Mechanism of cultured endothelial injutry by lymphokine activated killer cells. Cancer Res 48:5528, 1988
44. Mier JW, Brandon EP, Cibby P, Janicka MW, Aronsos FR: Activated endothelial cells resist lymphokine activated killer cell-mediated injury. J Immunol 143:2407, 1989
45. Manabe A, Murti KG, Coustan-Smith E, Kumagai M, Behm FG, Raimondi SC, Campana D: Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood 83:758, 1994
46. Murti KG, Brown PS, Kumagai M, Campana D: Molecular interactions between human B-cell progenitors an the bone marrow microenvironment. Exp Cell Res 226:47, 1996
47. Kitayama J, Tsuno N, Yasuhara H, Nagawa H, Kimura W, Kuroda A, Shibata Y, Juji T, Muto T: Lysis of endothelial cells by autologous lymphokine-activated killer cells. Cancer Immunol Immunother 38:317, 1993
48. Zambello R, Trentin L, Enthammer C, Cipriani A, Agostini C, Semenzato G: Lysis of pulmonary fibroblasts by lymphokine (IL-2)-activated killer cells - A mechanism affecting the human lung microenvironment? Clin Exp Immunol 105:383, 1996
49. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238, 1992
50. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038, 1995
51. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9, 1995
52. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551, 1996
53. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549, 1998
54. Orentas RJ, Lemas MV, Mullin MJ, Colombani PM, Schwarz K, Ambinder R: Feasibility of cellular adoptive immunotherapy for Epstein-Barr virus-associated lymphomas using haploidentical donors. J Hematother 7:257, 1998
55. Brodie SJ, Lewinsohn DA, Patterson BK, Jiyamapa D, Krieger J, Corey L, Greenberg PD, Riddell SR: In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med 5:34, 1999
56. Roskrow MA, Suzuki N, Gan Yj, Sixbey JW, Ng CY, Kimbrough S, Hudson M, Brenner MK, Heslop HE, Rooney CM: Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 91:2925, 1998
57. + progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 95:10152, 1998
58. Curti BD, Ochoa AC, Powers GC, Kopp WC, Alvord WG, Janik JE, Cause BL, Dunn B, Kopreski MS, Fenton R, Zea A, Dansky-Ullmann C, Strobl S, Harvey L, Nelson E, Sznol M, Longo DL: Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. J Clin Oncol 16:2752, 199
59. Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM: Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94, 1996